<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39444354</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol Infect</ISOAbbreviation></Journal><ArticleTitle>The impact of COVID-19 status and vaccine type following the first dose on acute heart disease: A nationwide retrospective cohort study in South Korea.</ArticleTitle><Pagination><StartPage>e134</StartPage><MedlinePgn>e134</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e134</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268824001213</ELocationID><Abstract><AbstractText>Recent studies have suggested an increased incidence of myocarditis and pericarditis following mRNA vaccination or COVID-19. However, the potential interaction effect between vaccine type and COVID-19 on heart disease risk remains uncertain. Our study aimed to examine the impact of COVID-19 status and vaccine type following the first dose on acute heart disease in the Korean population, using data from the National Health Insurance Service COVID-19 database (October 2018-March 2022). We sought to provide insights for public health policies and clinical decisions pertaining to COVID-19 vaccination strategies. We analysed heart disease risk, including acute cardiac injury, acute myocarditis, acute pericarditis, cardiac arrest, and cardiac arrhythmia, in relation to vaccine type and COVID-19 within 21 days after the first vaccination date, employing Cox proportional hazards models with time-varying covariates. This study included 3,350,855 participants. The results revealed higher heart disease risk in individuals receiving mRNA vaccines than other types (adjusted HR, 1.48; 95% CI, 1.35-1.62). Individuals infected by SARS-CoV-2 also exhibited significantly higher heart disease risk than those uninfected (adjusted HR, 3.56; 95% CI, 1.15-11.04). We found no significant interaction effect between vaccine type and COVID-19 status on the risk of acute heart disease. Notably, however, younger individuals who received mRNA vaccines had a higher heart disease risk compared to older individuals. These results may suggest the need to consider alternative vaccine options for the younger population. Further research is needed to understand underlying mechanisms and guide vaccination strategies effectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Choa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computing, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yaeji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computing, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Seok-Jae</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Namhui</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computing, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Inkyung</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-3780-3213</Identifier><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="Y">Heart Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">adverse event</Keyword><Keyword MajorTopicYN="N">heart disease</Keyword><Keyword MajorTopicYN="N">vaccine safety surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444354</ArticleId><ArticleId IdType="pmc">PMC11502425</ArticleId><ArticleId IdType="doi">10.1017/S0950268824001213</ArticleId><ArticleId IdType="pii">S0950268824001213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jung J (2021) Preparing for the coronavirus disease (COVID-19) vaccination: Evidence, plans, and implications. Journal of Korean Medical Science 36, e59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900528</ArticleId><ArticleId IdType="pubmed">33619920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortner A and Schumacher D (2021) First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries (Craiova) 9, e122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101362</ArticleId><ArticleId IdType="pubmed">33969180</ArticleId></ArticleIdList></Reference><Reference><Citation>Food U and Administration D (2021) Vaccines and related biological products Advisory Committee Meeting: EUA Amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 5 through 11 years of age. In: United States. Food and Drug Administration. United States. Food and Drug Administration.</Citation></Reference><Reference><Citation>Polack FP, et al. (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine 383, 2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine 384, 403–416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B (2023) Shedding light on mechanisms of myocarditis with COVID-19 mRNA vaccines. Circulation 147, 877–880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10010664</ArticleId><ArticleId IdType="pubmed">36794591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D, et al. (2021) Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. New England Journal of Medicine 385, 2140–2149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531987</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilonze OJ and Guglin ME. (2022) Myocarditis following COVID-19 vaccination in adolescents and adults: A cumulative experience of 2021. Heart Failure Reviews 27, 2033–2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023259</ArticleId><ArticleId IdType="pubmed">35449353</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster ME, et al. (2022) Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. The Journal of the American Medical Association 327, 331–340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, et al. (2022) Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review. Annals of Medicine and Surgery 76, 103486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912977</ArticleId><ArticleId IdType="pubmed">35291413</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug A, Stevenson J and Høeg TB. (2022) BNT162b2 vaccine-associated myo/pericarditis in adolescents: A stratified risk-benefit analysis. European Journal of Clinical Investigation 52, e13759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111575</ArticleId><ArticleId IdType="pubmed">35156705</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoto PDMC, et al. (2023) Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination. npj Vaccines 8, 89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10252172</ArticleId><ArticleId IdType="pubmed">37296167</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerstedt S, Casaro EB and Rangel ÉB (2021) COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European Journal of Clinical Microbiology &amp; Infectious Diseases 40, 905–919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778857</ArticleId><ArticleId IdType="pubmed">33389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin KJ, et al. (2020) COVID-19 and cardiovascular disease. Circulation 141, 1648–1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N and Balicer RD (2021) Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. New England Journal of Medicine 385, 2299–2299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609601</ArticleId><ArticleId IdType="pubmed">34706169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M (2020) Cardiovascular disease and COVID-19. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews 14, 247–250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Freise NF, et al. (2022) Acute cardiac side effects after COVID-19 mRNA vaccination: A case series. European Journal of Medical Research 27, 1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9160507</ArticleId><ArticleId IdType="pubmed">35655235</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, et al. (2021) Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. New England Journal of Medicine 385, 1078–1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, et al. (2021) Myocarditis after COVID-19 vaccination in a large health care organization. New England Journal of Medicine 385, 2132–2139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531986</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazlollahi A, et al. (2022) Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series. Reviews in Medical Virology 32, e2318.</Citation><ArticleIdList><ArticleId IdType="pubmed">34921468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidik SM (2022) Heart-disease risk soars after COVID – Even with a mild case. Nature 602, 560.</Citation><ArticleIdList><ArticleId IdType="pubmed">35145295</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, et al. (2022) Long-term cardiovascular outcomes of COVID-19. Nature Medicine 28, 583–590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Caforio AL, et al. (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. European Heart Journal 34, 2636–2648.</Citation><ArticleIdList><ArticleId IdType="pubmed">23824828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kociol RD, et al. (2020) Recognition and initial management of fulminant myocarditis: A scientific statement from the American Heart Association. Circulation 141, e69–e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kühl U, et al. (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111, 887–893.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699250</ArticleId></ArticleIdList></Reference><Reference><Citation>He X-W, et al. (2020) Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi 48, 456–460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-I, et al. (2020) SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm 17, 1456–1462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156157</ArticleId><ArticleId IdType="pubmed">32244059</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J, et al. (2021) The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: A meta-analysis. The American Journal of Emergency Medicine 48, 128–139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056484</ArticleId><ArticleId IdType="pubmed">33895644</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, et al. (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Babapoor-Farrokhran S, et al. (2020) Myocardial injury and COVID-19: Possible mechanisms. Life Sciences 253, 117723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194533</ArticleId><ArticleId IdType="pubmed">32360126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cusick MF, Libbey JE and Fujinami RS (2012) Molecular mimicry as a mechanism of autoimmune disease. Clinical Reviews in Allergy &amp; Immunology 42, 102–111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266166</ArticleId><ArticleId IdType="pubmed">22095454</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. (2006) Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. The Journal of Immunology 177, 8234–8240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A and Kharrazian D (2020) Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology 217, 108480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7246018</ArticleId><ArticleId IdType="pubmed">32461193</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Y, et al. (2022) Myocarditis following coronavirus disease 2019 mRNA vaccine: A case series and incidence rate determination. Clinical Infectious Diseases 75, e749–e754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767838</ArticleId><ArticleId IdType="pubmed">34734240</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosano G, et al. (2021) COVID‐19 vaccination in patients with heart failure: A position paper of the heart failure Association of the European Society of cardiology. European Journal of Heart Failure 23, 1806–1818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652673</ArticleId><ArticleId IdType="pubmed">34612556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, et al. (2022) Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease. Cardiovascular Research 118, 2329–2338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278175</ArticleId><ArticleId IdType="pubmed">35732274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez GA, et al. (2022) Cardiac safety of mRNA-based vaccines in patients with systemic lupus erythematosus and lupus-like disorders with a history of myocarditis. Pathogens 11, 1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9502100</ArticleId><ArticleId IdType="pubmed">36145434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, et al. (2023) BNT162b2 or CoronaVac vaccinations are associated with a lower risk of myocardial infarction and stroke after SARS‐CoV‐2 infection among patients with cardiovascular disease. Journal of the American Heart Association 12, e029291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10227224</ArticleId><ArticleId IdType="pubmed">37119083</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>